Immune checkpoint inhibitors, which unleash the immune response against tumor cells, have revolutionized cancer treatment; however, the medications aren’t effective in a large number of patients, including those with colorectal cancer. Now, new research led by investigators at Harvard-affiliated Massachusetts General Hospital and the University of Geneva and published in PNAS provides insights on why… Read More »
Herbs and spices have been used as food preservatives, flavorings, and in traditional medicines for thousands of years. More and more scientific evidence supports the medicinal properties of culinary herbs. Colon cancer is the the fourth most common form of cancer worldwide. Studies show that Garlic, Ginger, Turmeric, Thyme, Rosemary, Sage, Spearmint, and Peppermint all… Read More »
Research Highlights: People who take angiotensin converting enzyme inhibitors (ACE-i) or angiotensin II receptor blockers (ARBs) for conditions such as high blood pressure were less likely to be diagnosed with colorectal cancer after having a normal colonoscopy. This is the first study to show potential benefits on colorectal cancer development from these commonly prescribed hypertension… Read More »
Print this page April 8, 2020 – Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, as detected by an FDA-approved test, after prior… Read More »
Colorectal cancer is the third most common cancer in the world. Researchers currently assume that the disease is 35 percent hereditary. The main risk factors include a family history of the disease. In recent years, researchers have also identified around 100 tiny gene variations that are widespread in the population (single nucleotide polymorphisms – SNPs)… Read More »
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. There is strong evidence that screening for CRC with colonoscopy, other visual exams, or stool-based tests can reduce CRC mortality. As a result, several expert organizations have long recommended regular CRC screening for US adults ages 50 to 75. In… Read More »